JPRN-UMIN000034704Completed未知
oninferior crossover study to evaluate blood testosterone improvement using new testosterone gel. - The study to evaluate blood testosterone improvement using new testosterone gel.
Juntendo University Urayasu Hospital0 sites20 target enrollmentStarted: October 30, 2018Last updated:
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Completed
- Enrollment
- 20
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 40years-old to 75years-old (—)
- Sex
- Male
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Prostatic cancer Polycythemia Sleep apnea syndrome
Investigators
Similar Trials
Recruiting
Not Applicable
A pilot study; The relationship between blood test during cardiopulmonary bypass and coagulation function evaluated by thromboelastometry after taking off cardiopulmonary bypass.Patients who receive cardiac surgeryJPRN-UMIN000037138agoya University Hospital50
Completed
Not Applicable
A study to evaluate the response of whole blood stimulation with lipopolysaccharide or other inducers and its in vitro inhibition in healthy volunteers, and patients with a chronic inflammatory conditioatherosclerose100110821000321610003816rheumatoid arthritisNL-OMON38316Centre for Human Drug Research250
Completed
Not Applicable
Control of Helicobacter pylori by a specific strain of Lactobacillus reuteriHelicobacter pyloriInfections and InfestationsHelicobacter pylori [H.pylori] as the cause of diseases classifiedISRCTN70607306onza Ltd (Switzerland)20
Recruiting
Not Applicable
Development of a better screening test for bowel cancer.colorectal cancer.Cancer - Bowel - Back passage (rectum) or large bowel (colon)ACTRN12611000318987Flinders Medical Centre5,000
Active, not recruiting
Not Applicable
An open-label study to investigate blood concentrations, safety, tolerability and efficacy of Elidel® Cream 1% in patients with moderate or severe seborrheic dermatitis treated topically for 3 weeks. - M2308Seborrheic dermatitisEUCTR2004-004275-11-DEovartis Pharma Services AG22